You have 3 free articles left this month. Get your free Basic subscription now and gain instant access to more.

Bulgaria's Sopharma cons net profit increases in H1

Author Radina Veleva
Bulgaria's Sopharma cons net profit increases in H1 Sopharma/ All rights reserved

SOFIA (Bulgaria), August 30 (SeeNews) - Bulgarian drug maker Sopharma [BUL:SFA] said on Monday that its consolidated net profit swelled to some 32.2 million levs ($19.4 million/16.5 million euro) in the first half of 2021, from 20.6 million levs a year earlier.

The company's sales revenue grew to some 759 million levs in the six months through June, from 679 million levs in the comparable period of 2020, the drug manufacturer said in an interim financial statement.

Sopharma's operating expenses rose to some 725.1 million levs in the period under review, from 652.3 million levs a year earlier, as cost of goods sold increased to some 557.9 million levs from 486.3 million levs.

Sales revenue in Ukraine rose by 600,000 levs, while in Russia, Kazakhstan and Poland it dropped by 13 million levs, 1.1 million levs and 100,000 levs, respectively.

As at 14:00 CET, shares in Sopharma traded flat at 3.54 levs on the Bulgarian Stock Exchange (BSE).

(1 euro = 1.95583 levs)

Share this story
SeeNews in Brief

View our Newsletters

 
Compare